Capital Management Associates Inc Cuts Stock Position in Eli Lilly and Company $LLY

Key Points

• Capital Management Associates Inc reduced its stake in Eli Lilly and Company (LLY) by 49.9% in the second quarter, now holding just 416 shares valued at $324,000.
• Eli Lilly reported earnings of $6.31 per share for the last quarter, exceeding analysts' expectations and showing a 37.6% increase in revenue compared to the same period last year.
• CEO David A. Ricks purchased 1,632 shares at an average price of $644.77, increasing his ownership stake in the company.

Capital Management Associates Inc lessened its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 49.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 416 shares of the company's stock after selling 414 shares during the quarter. Capital Management Associates Inc's holdings in Eli Lilly and Company were worth $324,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of LLY. PNC Financial Services Group Inc. raised its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $4,613,912,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC grew its holdings in Eli Lilly and Company by 7,975.5% during the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock worth $647,225,000 after acquiring an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company stock opened at $845.55 on Thursday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $800.28 billion, a price-to-earnings ratio of 55.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The stock's fifty day moving average is $738.69 and its two-hundred day moving average is $766.57.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on LLY shares. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $943.00.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.